five years ago

Five years ago POH shares were in excess of 40c on the back of the following announcement:
12 October, 2006
Page 2 of 3
Completion of Phosphagenics? transdermal insulin (TPM-02/Insulin) clinical
trial confirming the successful delivery of insulin across skin in humans
Phosphagenics Limited (?Phosphagenics?) (ASX: POH) (AIM: PSG) announced today that it has received the final report of its Phase I transdermal insulin clinical trial.
The final report confirms the conclusions of the interim results announced in August, that Phosphagenics had successfully delivered insulin through the skin in humans by means of its patented TPM-02/Insulin delivery system. The key findings as previously announced,
were that TPM-02/Insulin, when applied as a gel, delivered insulin through the skin and into the bloodstream and exerted its physiological effect of lowering blood glucose levels.
Importantly, TPM-02/Insulin did not produce any adverse reactions.
The new finding contained in the final study report was the detection of exogenous insulin
(externally-applied insulin) in the circulation of volunteers who received TPM-02/Insulin.
This additional data, in conjunction with the blood glucose, endogenous insulin and cpeptide results of the trial announced in August, demonstrate the ability of TPM-02/Insulin to deliver insulin into the blood stream and to produce significant effects

They surely must be cheap now.

Kens